	US 12,285,448 B2
	Bifidobacterium breve capable of relieving rheumatoid arthritis and application thereof
Bo Yang, Wuxi (CN); Wei Chen, Wuxi (CN); Zhexin Fan, Wuxi (CN); Qixiao Zhai, Wuxi (CN); Gang Wang, Wuxi (CN); Wenwei Lu, Wuxi (CN); Shumao Cui, Wuxi (CN); Jianxin Zhao, Wuxi (CN); and Hao Zhang, Wuxi (CN)
Filed by Jiangnan University, Wuxi (CN)
Filed on Mar. 17, 2022, as Appl. No. 17/696,959.
Application 17/696,959 is a continuation of application No. PCT/CN2021/107916, filed on Jul. 22, 2021.
Claims priority of application No. 202010913384.1 (CN), filed on Sep. 3, 2020.
Prior Publication US 2022/0211776 A1, Jul. 7, 2022
Int. Cl. A61K 35/745 (2015.01); A23L 2/52 (2006.01); A23L 33/00 (2016.01); A23L 33/135 (2016.01); A61P 19/02 (2006.01)

CPC A61K 35/745 (2013.01) [A23L 2/52 (2013.01); A23L 33/135 (2016.08); A23L 33/40 (2016.08); A61P 19/02 (2018.01); A23V 2002/00 (2013.01); A23V 2400/519 (2023.08)]

6 Claims

1. A drug, comprising:

freeze-dried Bifidobacterium breve (B. breve) CCFM1078; and

a protective agent,

wherein the B. breve is preserved at the Guangdong Microbial Culture Collection Center on May 6, 2020, with the preservation number GDMCC No: 61011,

wherein the B. breve comprises an 16S rDNA sequence set forth in SEQ ID NO: 1 and a genome of 2.36 Mb, and a G+C content of 58.90%, and

wherein the protective agent is selected from one or more of skim milk, trehalose, and sucrose.